Department of Gastroenterology, Research Center for Engineering Techniques of Microbiota-Targeted Therapies of Guangdong Province, The First Affiliated Hospital of Guangdong Pharmaceutical University, Nonglinxia Road 19, Guangzhou, 510000, China.
Guangdong Provincial Key Laboratory of Microbial Safety and Health, State Key Laboratory of Applied Microbiology Southern China, Institute of Microbiology, Guangdong Academy of Sciences, Xianliezhong Road 100, Guangzhou, 510000, China.
J Transl Med. 2023 Oct 19;21(1):740. doi: 10.1186/s12967-023-04570-0.
Changes in the gut microbiota composition is a hallmark of chronic kidney disease (CKD), and interventions targeting the gut microbiota present a potent approach for CKD treatment. This study aimed to evaluate the efficacy and safety of washed microbiota transplantation (WMT), a modified faecal microbiota transplantation method, on the renal activity of patients with renal dysfunction.
A comparative analysis of gut microbiota profiles was conducted in patients with renal dysfunction and healthy controls. Furthermore, the efficacy of WMT on renal parameters in patients with renal dysfunction was evaluated, and the changes in gut microbiota and urinary metabolites after WMT treatment were analysed.
Principal coordinate analysis revealed a significant difference in microbial community structure between patients with renal dysfunction and healthy controls (P = 0.01). Patients with renal dysfunction who underwent WMT exhibited significant improvement in serum creatinine, estimated glomerular filtration rate, and blood urea nitrogen (all P < 0.05) compared with those who did not undergo WMT. The incidence of adverse events associated with WMT treatment was low (2.91%). After WMT, the Shannon index of gut microbiota and the abundance of several probiotic bacteria significantly increased in patients with renal dysfunction, aligning their gut microbiome profiles more closely with those of healthy donors (all P < 0.05). Additionally, the urine of patients after WMT demonstrated relatively higher levels of three toxic metabolites, namely hippuric acid, cinnamoylglycine, and indole (all P < 0.05).
WMT is a safe and effective method for improving renal function in patients with renal dysfunction by modulating the gut microbiota and promoting toxic metabolite excretion.
肠道微生物群落组成的改变是慢性肾脏病(CKD)的一个标志,而针对肠道微生物群的干预措施为 CKD 的治疗提供了一种有效的方法。本研究旨在评估经改良的粪便微生物群移植(WMT),即洗必泰菌群移植,对肾功能障碍患者的肾脏活性的疗效和安全性。
对肾功能障碍患者和健康对照者的肠道微生物群谱进行了比较分析。此外,评估了 WMT 对肾功能障碍患者的肾脏参数的疗效,并分析了 WMT 治疗后肠道微生物群和尿液代谢物的变化。
主坐标分析显示肾功能障碍患者和健康对照组之间的微生物群落结构存在显著差异(P = 0.01)。与未接受 WMT 治疗的患者相比,接受 WMT 的肾功能障碍患者的血清肌酐、估计肾小球滤过率和血尿素氮均有显著改善(均 P < 0.05)。与 WMT 治疗相关的不良事件发生率较低(2.91%)。WMT 后,肾功能障碍患者的肠道微生物群 Shannon 指数和几种益生菌的丰度显著增加,其肠道微生物组谱与健康供体更接近(均 P < 0.05)。此外,WMT 后患者的尿液中三种毒性代谢物(即马尿酸、肉桂酰甘氨酸和吲哚)的水平相对较高(均 P < 0.05)。
WMT 通过调节肠道微生物群和促进毒性代谢物的排泄,是改善肾功能障碍患者肾功能的一种安全有效的方法。